Research questions: What are the major problems facing Vaxess Technologies? What are the factors that generated these issues? What can be done to enhance the current state of Vaxess Technologies?
Table of Contents
1. Introduction
1.1 Background of the study
1.2 Statement of the problem
1.3 Research questions
1.4 Research objectives
1.5 Structure of research
2. Case brief
2.1 SWOT analysis of Vaxess Technologies
3. Problem Statement and Plan of analysis
3.1 Problem statement
3.2 Plan of analysis
4. Case Analysis and Findings
4.1 Analysis
4.2 Findings
5. Solutions and Recommendations
5.1 Solutions
5.2 Action Plan
5.3 Limitations
5.4 Scope for further research
Research Objectives and Thematic Focus
This case study examines the strategic challenges faced by Vaxess Technologies, a biotechnology firm attempting to commercialize innovative silk protein technology for vaccine stabilization. The primary research objective is to identify the major obstacles preventing market entry—specifically financial constraints and partnership issues—and to propose a viable commercialization and strategic path forward.
- Strategic commercialization of novel silk protein vaccine stabilization technology.
- Overcoming high R&D costs and navigating strict regulatory requirements.
- Evaluating potential partnerships with pharmaceutical companies versus government organizations.
- Application of management models including Porter’s Five Forces, Ansoff Matrix, and Blue Ocean Strategy to inform decision-making.
Excerpt from the Book
1.1 Background of the study
Vaxess Technologies Inc. was established as an initiative of four entrepreneurs: Michael Schrader, who is chief executive of the firm; Kathryn Kosuda, who is responsible for the research and development; Patrick Ho, who is lawyer and looks after operations and legal affairs and Livio Valenti – responsible for policy and strategy (Vaxess, 2016). The company had obtained exclusive license to patents of silk protein technology from Tuffts University in 2013. The aim of the company is to enhance access to vaccines globally by eliminating requirement of cold storage of the goods between manufacture and usage. Silk protein that is main ingredient of the innovative technology if it is added to vaccines makes the medicine more stable at high temperature and allows vaccines to be transported without the necessity for refrigeration. This technology can work on both existing vaccines such as measles or mumps and those that are still in development (Joseph, 2015). Therefore, the firm decided to licence vaccine stabilizer such as the properties of silk fibroin from Tuffs University and looked for the ways of commercialization of this unique technology. To commercialize the innovative product and enter the market, Vaxess has to implement several tests and examinations in order to prove efficacy of the silk technology. The development of the further studies is time consuming and expensive therefore the firm wants to find a partner who will cover the cost of research (Cohan, 2012). The pharmaceutical companies such as Sanofi, Pasteur, Merck, GlaxoSmithKline, Novartis, Johnson&Johnson or Takeda which constitute 85% of the sold vaccines worldwide or the largest customers of the vaccines such as governments and international organizations like UNICEF, GAVI, Bill&Melinda Foundation, PAHO or PATH can constitute potential partner for Vaxess (Quelch et al. 2014). The company's aim is to enter the market in quickest possible time frame. However, currently Vaxess lacks financial resources to sustain a lengthy research, therefore it debates which partner will be suitable either pharmaceutical company or governmental organization.
Summary of Chapters
Chapter 1: Provides an introduction to the study, outlining the company background, the problem statement, research objectives, and research questions.
Chapter 2: Outlines the current state of Vaxess Technologies and provides a SWOT analysis.
Chapter 3: Details the primary challenges the company faces and presents the analytical models used to evaluate the case.
Chapter 4: Discusses the detailed analysis and findings derived from applying various management theories and models.
Chapter 5: Recommends solutions for the identified problems, proposes an action plan, and discusses the study's limitations and future research scope.
Keywords
Vaxess Technologies, Silk Protein Technology, Vaccine Stabilization, Cold Chain, Biotechnology, Pharmaceutical Partnership, Innovation Management, Strategic Management, Commercialization, Market Entry, Porter’s Five Forces, Licensing, R&D, Competitive Advantage, SWOT Analysis.
Frequently Asked Questions
What is the core focus of this research?
The research focuses on the business and strategic challenges encountered by Vaxess Technologies in bringing its proprietary silk-based vaccine stabilization technology to the global market.
What are the primary themes discussed in the work?
Key themes include commercialization strategy, financial resource allocation for R&D, navigating regulatory compliance, and the selection of suitable industry partners.
What is the main objective of the analysis?
The main objective is to identify how Vaxess can overcome its financial and operational hurdles to successfully launch its product, specifically by choosing between different types of corporate and governmental partnerships.
Which scientific or management methods are utilized?
The study utilizes a variety of frameworks including Porter’s Five Forces, the 5 Ps of marketing, the Ansoff Matrix, the Product Life Cycle, Value Chain analysis, the Ishikawa diagram, and the Blue Ocean Strategy (ERRC grid).
What is covered in the main body of the work?
The main body covers a comprehensive review of the company's current state, an in-depth analysis using management models, and the formulation of recommendations based on those findings.
Which keywords characterize this paper?
Key terms include Vaxess Technologies, silk protein, vaccine stabilization, commercialization, biotechnology, and strategic partnership.
Why does Vaxess need a partner?
Vaxess lacks the significant financial resources required to perform the expensive and time-consuming long-term tests necessary to gain regulatory approval and bring their product to market.
Why did Vaxess shift its partnership strategy?
The firm initially partnered with government agencies, but moved toward pharmaceutical manufacturers because they required a partner with profit-driven incentives capable of bringing the product to market more quickly.
What action plan is specifically recommended for Vaxess?
The paper recommends a joint venture strategy with a major firm like Novartis to leverage their established infrastructure, capital, and global market presence.
- Citar trabajo
- MBA graduate Katarzyna Szydlowska (Autor), 2018, What are the major problems facing Vaxess Technologies?, Múnich, GRIN Verlag, https://www.grin.com/document/421551
